Evaluation of Bleeding in Patients Receiving Direct Oral Anticoagulants

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2017 Sep 2

PMID 28860793

Citations 37

Authors

Erika L Hellenbart

Kathleen D Faulkenberg

Shannon W Finks

Affiliations

Soon will be listed here.

Abstract

Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the treatment of venous thromboembolism and prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. As use of these anticoagulants has become favored over the past several years, reported bleeding-related adverse drug events with these agents has increased. In randomized clinical trials, all DOACs have a reduced risk for intracranial hemorrhage, while major and other bleeding results have varied among the agents compared to vitamin K antagonists. We have reviewed the bleeding incidence and severity from randomized and real-world data in patients receiving DOACs in an effort to provide the clinician with a critical review of bleeding and offer practical considerations for avoiding adverse events with these anticoagulants.

Citing Articles

Venous thromboembolism treatment failure during use of factor Xa inhibitors-association with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension.

Kaksonen M, Simonen P, Lassila R, Pentikainen M Ann Med. 2024; 56(1):2404549.

PMID: 39624963 PMC: 11616765. DOI: 10.1080/07853890.2024.2404549.

Optimal timing of oral anticoagulation initiation in patients with acute ischaemic stroke and atrial fibrillation: a comprehensive meta-analysis and systematic review.

Dilli Babu A, Singh S, Gorantla A, Ali Baig M, Bhutani R, Davuluri H Open Heart. 2024; 11(2).

PMID: 39608862 PMC: 11603680. DOI: 10.1136/openhrt-2024-003002.

The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo.

Grafeneder J, Langer G, Schoergenhofer C, Eskandary F, Jilma B, Khder Y J Thromb Thrombolysis. 2024; 57(8):1339-1348.

PMID: 39549166 PMC: 11645315. DOI: 10.1007/s11239-024-03059-x.

Discovery of Heparin Mimetic, Potent, and Selective Inhibitors of Human Clotting Factor XIIIa.

Vu K, Kar S, Goyal N, Mottamal M, Afosah D, Al-Horani R ACS Omega. 2024; 9(28):31105-31119.

PMID: 39035933 PMC: 11256326. DOI: 10.1021/acsomega.4c04518.

Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial.

Pfeffer M, Kohs T, Vu H, Jordan K, Wang J, Lorentz C Arterioscler Thromb Vasc Biol. 2023; 44(1):290-299.

PMID: 37970718 PMC: 10877270. DOI: 10.1161/ATVBAHA.123.319692.

References

Majeed A, Hwang H, Connolly S, Eikelboom J, Ezekowitz M, Wallentin L . Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013; 128(21):2325-32. DOI: 10.1161/CIRCULATIONAHA.113.002332. View

Gage B, Yan Y, E Milligan P, Waterman A, Culverhouse R, Rich M . Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151(3):713-9. DOI: 10.1016/j.ahj.2005.04.017. View

Bleker S, Cohen A, Buller H, Agnelli G, Gallus A, Raskob G . Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016; 116(6):1159-1164. DOI: 10.1160/TH16-02-0137. View

Halvorsen S, Ghanima W, Tvete I, Hoxmark C, Falck P, Solli O . A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2016; 3(1):28-36. PMC: 5216196. DOI: 10.1093/ehjcvp/pvw031. View

Hernandez I, Baik S, Pinera A, Zhang Y . Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2014; 175(1):18-24. PMC: 6608584. DOI: 10.1001/jamainternmed.2014.5398. View

Camm A, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S . XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2015; 37(14):1145-53. PMC: 4823634. DOI: 10.1093/eurheartj/ehv466. View

Hernandez I, Smith K, Zhang Y . Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2016; 150:123-130. DOI: 10.1016/j.thromres.2016.10.006. View

Hylek E, Held C, Alexander J, Lopes R, De Caterina R, Wojdyla D . Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014; 63(20):2141-2147. DOI: 10.1016/j.jacc.2014.02.549. View

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):e199-267. PMC: 4676081. DOI: 10.1161/CIR.0000000000000041. View

10.

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

11.

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

12.

Buller H, Decousus H, Grosso M, Mercuri M, Middeldorp S, Prins M . Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15):1406-15. DOI: 10.1056/NEJMoa1306638. View

13.

Bassand J, Accetta G, Camm A, Cools F, Fitzmaurice D, Fox K . Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016; 37(38):2882-2889. PMC: 5070447. DOI: 10.1093/eurheartj/ehw233. View

14.

Prins M, Lensing A, Bauersachs R, van Bellen B, Bounameaux H, Brighton T . Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013; 11(1):21. PMC: 3850944. DOI: 10.1186/1477-9560-11-21. View

15.

Lip G, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R . Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost. 2016; 116(5):975-986. DOI: 10.1160/TH16-05-0403. View

16.

Rogers K, Shelton M, Finks S . Reversal Agents for Direct Oral Anticoagulants: Understanding New and Upcoming Options. Cardiol Rev. 2016; 24(6):310-315. DOI: 10.1097/CRD.0000000000000118. View

17.

Apostolakis S, Lane D, Guo Y, Buller H, Lip G . Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with.... J Am Coll Cardiol. 2012; 60(9):861-7. DOI: 10.1016/j.jacc.2012.06.019. View

18.

Hariharan S, Madabushi R . Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol. 2011; 52(1 Suppl):119S-25S. DOI: 10.1177/0091270011415527. View

19.

Fang M, Go A, Chang Y, Borowsky L, Pomernacki N, Udaltsova N . A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011; 58(4):395-401. PMC: 3175766. DOI: 10.1016/j.jacc.2011.03.031. View

20.

Graham D, Reichman M, Wernecke M, Zhang R, Southworth M, Levenson M . Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2014; 131(2):157-64. DOI: 10.1161/CIRCULATIONAHA.114.012061. View